Nimbus Therapeutics - NDI-034858 - Ownership and Business Overview

Life ScienceCompany

Nimbus Therapeutics - NDI-034858 Ownership

Who owns Nimbus Therapeutics - NDI-034858?

Nimbus Therapeutics - NDI-034858 is owned by Takeda Pharmaceutical. It was acquired on December 13, 2022.

Nimbus Therapeutics - NDI-034858 Business Overview

Where is Nimbus Therapeutics - NDI-034858 headquartered?

Nimbus Therapeutics - NDI-034858 is headquartered in Cambridge, Massachusetts.

What sector is Nimbus Therapeutics - NDI-034858 in?

Nimbus Therapeutics - NDI-034858 is a life science company.

Life Science M&A Summary in 2022

Out of 60 sectors in the Mergr database, life science ranked 7 in number of deals in 2022. The largest life science acquisition in 2022 was Horizon Therapeutics Public Limited Company - which was acquired by Amgen for $27.8B.

Join Mergr to view all 285 acquisitions of life science companies in 2022, including 33 acquisitions by private equity firms, and 252 by strategics.

Nimbus Therapeutics - NDI-034858

Nimbus Therapeutics - NDI-034858

Cambridge, Massachusetts 02141
United States,

Nimbus Therapeutics's NDI-034858 is an oral, selective allosteric tyrosine kinase 2 (TYK2) inhibitor being evaluated for the treatment of multiple autoimmune diseases following successful recent Phase 2b results in psoriasis.


 Subscribe to unlock this and 201,882
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.5K Private Equity Firms
  • 193K M&A Transactions
  • 197K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 75K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.